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Edited by Ned ManteiAbstract Neprilysin-2 (NEP2) is a novel metallopeptidase
homologous to neprilysin (NEP), an enzyme involved in regula-
tion of neuropeptide signalling. NEP2 exists as two alternatively
spliced isoforms, NEP2 and NEP2D. In this study, we cloned and
expressed both human isoforms. Human NEP2 exists as a mem-
brane-bound and soluble enzyme, whereas human NEP2D exists
as two membrane-bound glycoforms, localised to the ER and
plasma membrane. Surprisingly, NEP2 substrate speciﬁcity
and inhibitor binding was distinct from that of human NEP, sug-
gesting that NEP and NEP2 play distinct physiological roles in
humans, and human NEP2 diﬀers markedly from its rodent
homologues.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The zinc metallopeptidases are responsible for both activa-
tion and hydrolysis of bioactive peptide hormones and neuro-
peptides [1]. Within this group, the neprilysin (M13) family has
been implicated in several pathologies including cardiovascular
disease, prostate cancer and Alzheimers disease [2]. The seven
known mammalian family members therefore represent impor-
tant therapeutic targets.
NEP2 cDNA was cloned from ECE-1 knockout mice in
1999 and originally named soluble secreted endopeptidase
(SEP) [3]. Other groups identiﬁed the equivalent neprilysin-2
(NEP2) from rat brain [4] and neprilysin-like 1 (NL1) from
mouse testis [5]. The MEROPS database has retained NEP2
as the oﬃcial nomenclature [6]. Alternative splicing of the ro-
dent NEP2 gene generates two products, NEP2 and NEP2D,
which diﬀer only by a 69 bp exon immediately after the trans-
membrane domain which is unique to NEP2 [7]. Both isoforms
are type II membrane proteins. CHO cells transfected with
mouse NEP2 secrete functional enzyme into the medium,
whereas cells transfected with NEP2D do not [3]. The unique
region of NEP2 contains a prohormone-convertase recogni-
tion site (Lys62–Arg63), suggesting soluble NEP2 may be pro-
teolytically released from membrane-bound NEP2.
In 2001, the MMEL2 gene encoding human NEP2 was
cloned from a human foetal brain library using mouse NEP2
cDNA as a probe [8]. The predicted protein product of 770*Corresponding author. Fax: +44 (0) 113 3433157.
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doi:10.1016/j.febslet.2008.05.046amino acids is 54% identical to human NEP. This study pre-
sents the ﬁrst data on the cell biology and speciﬁcity of human
NEP2 and reveals distinct diﬀerences in speciﬁcity from both
the rodent enzyme and from human NEP itself.2. Materials and methods
2.1. Cell culture
CHO cells were obtained from the ECACC (Salisbury, UK) and cul-
tured according to ECACC instructions (www.ecacc.org.uk).
2.2. Antibodies and materials
The rabbit polyclonal antibody Rb342 to human NEP2, raised
against the puriﬁed ectodomain of human NEP2D, was provided by
Solvay Pharmaceuticals (Hanover, Germany). NEP monoclonal anti-
body was from Novocastra (Newcastle, UK). The ectodomain of hu-
man recombinant NEP2D was provided by Solvay Pharmaceuticals.
Recombinant NEP was a gift from Dr. David Nanus (Cornell Univer-
sity, New York). Thiorphan, phosphoramidon and peptide substrates
were purchased from Sigma.2.3. cDNA constructs
NEP2 cDNA was ampliﬁed from human testis total RNA (Clon-
tech) using one-step RT-PCR and the following primers:
sense 5 0-CTACGCGGCCGCTACTGCTCTCCCATCCCAGTCC-
CT-3 0,
antisense 5 0-AGTCGTCTAGATCTTTGAAGCATTTACTTAGCT-
CA-3 0,
and subcloned into the NotI/XbaI sites of pcDNA3 (Invitrogen).
NEP2D cDNA was created by removal of exon three from NEP2
cDNA by site-directed mutagenesis. Both constructs were fully se-
quenced.2.4. Transfection
CHO cells were transfected at 30–50% conﬂuency using Lipofect-
amine (Invitrogen) according to manufacturers instructions. Cells or
medium were harvested 48 h post-transfection.
2.5. Collection of cell medium
Cells were grown to 80% conﬂuence, washed twice in serum-free
OptiMEM (Gibco) then incubated in OptiMEM for 24 h. Medium
was harvested and concentrated by centrifugation in 10 kDa Centricon
concentrators (VivaScience).
2.6. Membrane preparation
Total membrane protein was isolated from cells disrupted using N2
gas in aParr cell disruptionbomb (750 psi).Homogenateswere ultracen-
trifuged for 1 h at 104000·g and pelletedmembranes solubilised inMES
buﬀer (25 mMMES, 0.15 MNaCl, pH6.5) containing 1%TritonX-100.
2.7. Immunoblotting
Sample buﬀer containing 2% (v/v) b-mercaptoethanol was added
to samples which were analysed on a 6% (v/v) SDS–PAGE gel andblished by Elsevier B.V. All rights reserved.
Fig. 1. Expression of human NEP2 and NEP2D in CHO cells. CHO
cells were transiently transfected with NEP2 or NEP2D cDNA or
empty vector. (A) Membrane protein (M) or culture medium protein
(S) from each along with recombinant NEP2 ectodomain (+) were
analysed by immunoblotting using anti-NEP2 antibody. (B) Culture
medium or membrane protein was incubated with Endo H (H) or
PNGase F (F) overnight. Control samples () were incubated in
parallel without endoglycosidases. Samples were analysed by immu-
noblotting using anti-NEP2 antibody.
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Rb342 polyclonal anti-NEP2 (1:2000 overnight) followed by secondary
antibody (anti-rabbit HRP conjugate) for 1 h.
2.8. Immunoﬂuorescence
CHO cells were grown on coverslips in six-well plates, transiently
transfected, and immunostained as previously described [9]. Slides
were examined at high resolution using the DeltaVision Optical Resto-
ration Microscopy System (Applied Precision Inc., Issaquah, USA).
2.9. Endoglycosidase digestion
Samples were digested with endo-b-N-acetylglucosaminidase (Endo
H) or peptide-N-glycosidase F (PNGase F) (NEB) overnight according
to the manufacturers instructions.
2.10. Substrate hydrolysis assays
Assays were performed in a total volume of 100 ll containing
100 mM Tris–HCl pH 7.3, 100 ng recombinant protein and 100 lM
substrate. Reactions were incubated at 37 C for 1 h and terminated
by heating to 100 C for 5 min.
2.11. Inhibitor assays
Assays were performed in a total volume of 100 ll in 100 mM
Tris–HCl pH 7.3. Recombinant NEP (10 ng) or NEP2 (60 ng) was
pre-incubated with phosphoramidon or thiorphan for 15 min prior
to incubation with 50 lM bradykinin at 37 C for 1 h.
2.12. RP-HPLC analysis
Samples were separated on a 5 l C18 reverse-phase HPLC column at
a ﬂow rate of 1.5 ml/min. Mobile phase A was 0.02% (v/v) triﬂuoroace-
tic acid in water, and mobile phase B was 0.016% (v/v) triﬂuoroacetic
acid in acetonitrile. A linear gradient of 11–100% B over 15 min with
5 min at ﬁnal conditions, and 8 min re-equilibration was used.3. Results and discussion
3.1. Expression of NEP2
CHO cells were transiently transfected with human NEP2 or
NEP2D cDNA, and total membrane protein or media samples
analysed by immunoblot. NEP2 expression was detected in
both membrane and media fractions (Fig. 1A). The mem-
brane-bound isoform is approx 95 kDa whilst the soluble form
is approx 110 kDa. NEP2D was detected only in the membrane
fraction as two bands of 95 kDa and 120 kDa. In contrast, it
has been reported that rodent NEP2D exists only as a single
110 kDa membrane-bound isoform, whilst NEP2 exists as a
membrane-bound form and as a soluble enzyme of 126 kDa
[3,5]. The discrepancy in size is presumably due to species dif-
ferences. We also assayed the enzyme activity of the membrane
and media fractions by RP-HPLC using angiotensin I as the
substrate. Activity was detected in the NEP2 membrane frac-
tion (1.10 nmol/min/mg) and media fraction (5.17 nmol/min/
mg). Activity was also detected in the NEP2D membrane frac-
tion (3.56 nmol/min/mg), but was negligible in the NEP2D
media fraction. Proteolytic release of a soluble form of
NEP2 is unique amongst the M13 family of metallopeptidases
and the soluble form of NEP2 may function as a circulating
endopeptidase.
3.2. Deglycosylation of NEP2
The human NEP2 sequence contains seven potential N-gly-
cosylation sites [8]. Membrane and media fractions from trans-
fected CHO cells were treated with Endo H or PNGase F.
Proteins in the early secretory pathway are sensitive to both
Endo H and PNGase F, whilst transit through the Golgi appa-ratus renders proteins resistant to Endo H but susceptible to
PNGase F. The NEP2 membrane-bound isoform was sensitive
to both Endo H and PNGase F; treatment reduced its molec-
ular mass from 95 kDa to 85 kDa (Fig. 1B). This isoform is
therefore a partially glycosylated form present in the early
secretory pathway. NEP2 in culture medium was similarly sen-
sitive to PNGase F but insensitive to Endo H, implying soluble
NEP2 is completely glycosylated and has been secreted after
transit through the Golgi network. Both NEP2D membrane-
bound forms were sensitive to digestion by PNGase F, which
reduced the molecular weight to 85 kDa. Upon treatment with
Endo H, however, two distinct bands were seen. Endo H re-
duced the molecular weight of the 95 kDa band to 85 kDa
but the higher molecular weight band of 120 kDa appeared
insensitive to Endo H, implying that NEP2D exists as two dif-
ferently glycosylated forms. This has not been reported for the
rodent homologues and would appear to be unique to human
NEP2. It has been suggested that NEP2 is inactive in the ER
and needs to reach the Golgi apparatus to become active
[10]. It would therefore seem likely that both NEP2 and
NEP2D exist as an inactive form in the ER, and an active cir-
culating form (NEP2) or an active membrane-bound form
(NEP2D).
3.3. Subcellular localisation of NEP2 and NEP
CHO cells transiently transfected with NEP2, NEP2D or
NEP constructs were analysed by immunoﬂuorescence micros-
copy (Fig. 2). Human NEP2 colocalised with binding of con-
canavalin A indicating endoplasmic reticulum (ER)
localisation. NEP2D showed the same ER immunostaining pat-
tern but plasma membrane staining was also observed; this
likely represents the higher molecular weight, fully glycosyl-
ated membrane isoform seen by immunoblotting. NEP local-
ised almost exclusively to the plasma membrane. Transfected
HEK cells showed a similar staining pattern (data not shown).
Fig. 2. Localisation of NEP2, NEP2D and NEP in transfected CHO cells. CHO cells were transiently transfected with NEP2, NEP2D or NEP cDNA
and ﬁxed and permeabilised for immunoﬂuorescence microscopy. Protein was detected with polyclonal anti-NEP2 or monoclonal anti-NEP
antibody. Cells were also labelled with FITC concanavalin A (Con A) and counterstained with DAPI. Scale bar 10 lm.
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sively inside the cell [3,7], although it was recently reported
that HEK cells transfected with mouse NEP2D show limited
cell-surface activity [11]. Our novel data suggest that human
NEP2D, like NEP, can function at the plasma membrane as
an ectoenzyme. Resident ER proteins normally carry a Lys–
Asp–Glu–Leu (KDEL) retention signal. NEP2 does not
contain a KDEL motif so may contain an unidentiﬁed ER
localisation signal.
3.4. Analysis of substrate speciﬁcity
We next compared the substrate preferences of both NEP2
and NEP using RP-HPLC (Table 1). NEP eﬃciently hydroly-
sed substance P, bradykinin, angiotensin I, angiotensin II, leu-
cine-enkephalin, met-enkephalin, neurotensin and neurotensin
fragment 8–13 in line with previous ﬁndings [12]. Although res-
idues identiﬁed as being important for substrate binding and
hydrolysis in NEP [13] are all conserved in NEP2, there were
striking diﬀerences in hydrolysis rates between NEP and
NEP2. Only substance P and angiotensin I were eﬃciently
(>90%) hydrolysed by NEP2; bradykinin was partly hydroly-
sed (57%) but all other peptides were ineﬃciently (<25%)
hydrolysed. Numerous substrates including methionine
enkephalin, leucine-enkephalin, angiotensin II, neurotensinand the NEP ﬂuorogenic substrate dansyl-dAG-p-nitro-FG
were well hydrolysed by NEP but poorly hydrolysed by NEP2.
In contrast, previous work on rodent NEP2 found substrate
preferences similar to those of NEP [3,10]. Rodent NEP2 eﬃ-
ciently hydrolysed leucine and methionine enkephalin, and
bradykinin with speciﬁcity constants greater than or equal to
NEP [10].
Human NEP2 is 77.5% and 81% identical to mouse and rat
NEP2 respectively [8,14] whereas mouse and rat NEP2 are
91% identical; this may explain the disparity in substrate pref-
erence between human and rodent enzymes. The diﬀerence in
human NEP and NEP2 substrate hydrolysis suggests distinct
roles for the two enzymes. A knockout mouse has been devel-
oped; NEP2-null mice were viable and developed normally but
males produced fewer pups than wild-type mice [15]. NEP2 ap-
pears to be involved in sperm function in mice and modulates
fertilisation and early embryonic development [15]. Human
NEP2 may also be developmentally-regulated and play a spe-
ciﬁc role in the reproductive system, possibly explaining its
narrow substrate speciﬁcity.
3.5. Inhibitor characterisation
We next compared the eﬀects of thiorphan (a NEP-speciﬁc
inhibitor) and phosphoramidon (a metalloprotease inhibitor)
Table 1
Comparative hydrolysis (%) of peptide substrates by NEP2 and NEP
Substrate NEP2 NEP
Substance P RPKPQQFFGLM-NH2 100 ± 0.1 100 ± 0.1
Angiotensin I DRVYIHPFHL 92 ± 0.4 99 ± 0.2
Bradykinin RPPGFSPFR 57 ± 3.4 100 ± 0.2
NEP ﬂuorogenic substrate Suc-AAF-AMC 39 ± 1.6 100 ± 0.1
Met enkephalin YGGFM 25 ± 1.6 99 ± 0.2
Substance P 7–11 FGLM-NH2 17 ± 3.1 68 ± 1.7
Neurotensin 8–13 RRPYIL 14 ± 1.3 96 ± 0.2
Leucine enkephalin YGGFL 10 ± 0.1 99 ± 0.1
Angiotensin II DRVYIHPF 7 ± 0.6 98 ± 0.2
Neurotensin pELYENKPRRPYIL 6 ± 1.3 85 ± 0.2
Leucine enkephalinamide YGGFL-NH2 1.2 ± 0.8 62 ± 2.4
Endothelin-1 CSCSSLMDKECVYFCHLDIIW 1.2 ± 0.4 14 ± 2.9
Neurotensin 1–11 pELYENKPRRPY 0.7 ± 0.5 4.9 ± 0.4
Vasopressin CYFQNCPRG-NH2 0.6 ± 0.2 0.4 ± 0.2
Oxytocin CYIQNCPLG-NH2 0.4 ± 0.3 2.5 ± 0.5
Bradykinin 1–5 RPPGF 0.4 ± 0.2 0.9 ± 0.4
NEP ﬂuorogenic substrate Dansyl-dAG-p-nitro-FG 0.3 ± 0.1 77 ± 0.7
Substance P 1–7 RPKPQQF 0.2 ± 0.1 1.9 ± 0.3
NEP2D ectodomain (100 ng) or recombinant NEP (100 ng) was incubated with 100 lM substrate at 37 C for 1 h. Reactions were terminated by
heating at 100 C for 5 min and products analysed by reverse-phase HPLC. Results are an average of three independent experiments ±S.E.M.
Fig. 3. Inhibitory eﬀect of (A) phosphoramidon and (B) thiorphan.
Puriﬁed NEP (10 ng) and NEP2 (60 ng) were pre-incubated with
diﬀerent concentrations of inhibitor for 15 min prior to incubation
with bradykinin (50 lM) at 37 C for 30 min. Reactions were
terminated by heating to 100 C and the product quantiﬁed using
RP-HPLC. Data points are the average of three independent exper-
iments.
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more potent against NEP (IC50 22.1 nM) than NEP2 (IC50169 nM) (Fig. 3A). Thiorphan was far more potent against
NEP (IC50 6.9 nM) than NEP2 (IC50 22.1 lM) (Fig. 3B). This
follows the general trend seen in rodent NEP2, whereby phos-
phoramidon was equally potent against NEP and NEP2,
whilst thiorphan was far more eﬀective against NEP [10].
Important substitutions in the active sites of NEP and NEP2
may explain the diﬀerences observed in both substrate hydro-
lysis and inhibitor binding. The active site of rat NEP2 was re-
cently modelled on the X-ray structure of human NEP and
diﬀerences observed in the S 02 subsite (two glycine residues in
NEP are replaced with Leu739 and polar Ser133 in NEP2) which
were suﬃcient to cause diﬀerences in inhibitor and substrate
binding [16]. Currently no NEP2-speciﬁc inhibitors are avail-
able.
In conclusion, these data represent the ﬁrst characterisation
of human NEP2 and its unique processing mechanism. We
have identiﬁed important diﬀerences in the cell biology and
speciﬁcity of rodent and human NEP2. This work has also
highlighted signiﬁcant distinctions between human NEP and
NEP2, including a much restricted substrate speciﬁcity for
NEP2 compared with NEP, and diﬀerences in subcellular
localisation. Work to date has exclusively focused on rodent
NEP2 but our data highlight the limitations of this system,
especially as a means to studying the physiological role of hu-
man NEP2. Further work on human NEP2, including struc-
tural studies, may explain the diﬀerences observed and lead
towards an understanding of its physiological role and its po-
tential as a therapeutic target.
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